-
JAMA Oncology: High-dose radiotherapy for high-risk prostate cancer, what is the optimal duration of ADT?
Time of Update: 2022-05-01
Based on this situation and the lack of duration data to guide EBRT+BT treatment decisions, the researchers conducted this study to confirm Optimal ADT duration threshold associated with improved distant metastasis-free survival (DMFS) in high-risk prostate cancer patients .
-
ASCO-GU Highlight - Big coffee gathered, precision first, and look at the GU hot spots
Time of Update: 2022-05-01
Professor Bi Liangkuan said that the development of immunotherapy has promoted changes in treatment decisions in the UC field, especially neoadjuvant therapy, which has brought good benefits to patients .
-
Looking back at the anterior "gland" and exploring a new realm——the choice for accurate diagnosis and treatment of mCRPC patients
Time of Update: 2022-05-01
*For medical professionals to read for reference only, the experts in the field will show you the current situation and prospects of the field of prostate cancer diagnosis and treatment, and see how PARP inhibitors combined with abiraterone can become the accurate choice for the diagnosis and treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) .
-
The pivotal Phase 3 clinical results of the innovative antibiotic combination of Express Express are positive, and the new drug application is planned to be submitted this year
Time of Update: 2022-05-01
▎WuXi AppTec Content Team Editor A few days ago, Venatorx announced that its innovative antibiotic combination, cefepime/taniborbactam, is in a pivotal Phase 3 clinical trial in adult patients with complicated urinary tract infections, including acute pyelonephritis.
-
Courier Significantly Extends Lives in Selected Prostate Cancer Patients, Bayer's Innovative Combination Therapy Filed in Japan
Time of Update: 2022-05-01
▎WuXi AppTec content team editor Bayer recently announced that it has submitted an additional indication application for the oral androgen receptor inhibitor (ARi) darolutamide to the Japanese Ministry of Health, Labour and Welfare (MHLW), aiming to seek Approved for the treatment of patients with prostate cancer with distant metastases in combination with docetaxel and androgen deprivation therapy (ADT) .
-
The latest research on prostate cancer is listed in NEJM
Time of Update: 2022-05-01
▎Professor Dai Bo said: "In the past three to four years, mHSPC-related research has made considerable progress, and a variety of new androgen signaling pathway inhibitors have been applied in the treatment of mHSPC .
-
Summary of the article: diagnosis and treatment of special teratozoospermia
Time of Update: 2022-05-01
The characteristics of sperm motility and concentration in patients with round-headed spermatozoa still need to be further confirmed by large-scale studies, especially in combination with the analysis of disease-causing genes and mutation sites .
For the genetic diagnosis of patients with round-headed spermatozoa, it is recommended to first screen for DPY19L2 gene deletion or/and point mutation .
-
Divine Journal CA Precision Therapy Era: Prostate Cancer Germline Testing Is Indispensable, When Does "Hereditary" Cancer Need Genetic Testing
Time of Update: 2022-05-01
Progression-free survival (PFS) and overall survival (OS) data from multiple precision therapy studies suggest germline and/or somatic mutations in DNA repair genes (eg, BRCA1, BRCA2, ATM, PALB2, FANCA, RAD51D, and CHEK2) Patients with metastatic or advanced prostate cancer are more likely to benefit from PARP inhibitors and platinum-based chemotherapy .
-
Prof. Zeng Hao's 2022 ASCO GU Prostate Cancer Blockbuster Research Interpretation PROpel Research and MAGNITUDE Research
Time of Update: 2022-05-01
In 2018, the results of a small-sample, prospective phase II clinical trial published in Lancet Oncol showed that after the failure of first-line treatment, abiraterone combined with olaparib can make patients achieve very good radiological progression-free survival ( rPFS), but overall survival (OS) was not significantly improved .
-
A new era of prostate cancer treatment with ADT as the cornerstone from 2022 ASCO-GU
Time of Update: 2022-05-01
At this ASCO-GU conference, the third analysis of the FINITE trial of LHRH agonist (LHRHa) combined with abiraterone (AA) in the treatment of biochemically recurrent non-metastatic hormone-naïve prostate cancer (M0HNPC) patients confirmed the efficacy of LHRHa + AA.
-
Case sharing: Abiraterone has a significant effect of deeply relieving PSA, and the quality of the original drug is better
Time of Update: 2022-04-30
Figure 5 Changes in PSA values of patients during treatment with domestic abiraterone Metastasis, multiple bone metastases throughout the body, and tumor heterogeneity in some lesions, please combine clinical practice .
-
PSA deep rapid decline, OS long-term "ke" period, apalutamide + ADT long-term tumor control, bringing long-term survival hope to mHSPC patients classic case
Time of Update: 2022-04-30
3 The patient's prostate cancer biopsy results Diagnosis: mHSPC with multiple lymph node and bone metastases .
Subgroup analysis showed that apalutamide treatment benefited the vast majority of mHSPC patients, and the high tumor burden group significantly prolonged overall survival (OS) and reduced the risk of death by 30% compared with the placebo group .
-
EAU Guidelines for the Diagnosis and Treatment of Lower Urinary Tract Symptoms in Non-Neurogenic Women (Part 1)
Time of Update: 2022-04-30
Bladder training can be used as first-line treatment for adult patients with OAB/urge urinary incontinence (UUI) (strength of recommendation: strong) .
After a thorough discussion of the risks and benefits of other surgical modalities, urethral filler injections may be given to women seeking SUI (strength of recommendation: strong) .
-
Professor Zhang Shilong took the "Guide" and opened up the road of clinical exploration
Time of Update: 2022-04-30
However, in real diagnosis and treatment scenarios, urinary tract The conditions of prostate cancer patients faced by surgeons are often more complex, which requires doctors to carry out individualized treatment according to the actual situation, and also requires doctors to continuously verify and explore the guidelines according to practice .
-
The disappearance of symptoms in patients with ureteral stones does not mean that the stones are discharged
Time of Update: 2022-04-30
A recent study of patients presenting with pain due to ureteral stones found that the absence of pain within the next few weeks does not necessarily mean the stone has passed (NEJM JW Gen Med Jun 1 2018 and J Urol 2018; 199:1011) .
-
Clinical Essentials: Interpretation of Guidelines for Robot-Assisted Radical Prostatectomy via Transvesical Approach
Time of Update: 2022-04-30
Preoperative bowel preparation can be considered for patients with high risk of rectal injury assessed before operation; intraoperative use can be considered A rectal probe aids in positioning, and the surgeon and assistant collaborate to fully expose the plane of separation between the posterior surface of the prostate and the anterior wall of the rectum .
-
Leading the new era of precision: Pluvicto, the first radioligand therapy in the mCRPC field, was approved by the FDA!
Time of Update: 2022-04-29
On March 23, 2022, Pluvicto (lutetium Lu 177 vipivotide tetraxetan, 177Lu-PSMA-617) was approved by the FDA for the treatment of prostate-specific membrane antigen (PSMA)-positive patients who have received an androgen receptor (AR) inhibitor and taxane-based chemotherapy in adult patients with metastatic castration-resistant prostate cancer (mCRPC) .
-
Novartis nuclear drug approved by FDA: Pluvicto
Time of Update: 2022-04-29
On March 23, 2022, Novartis announced that 177Lu-PSMA-617 was approved by the FDA for the treatment of PSMA-positive, treatment-progressed castration-resistant prostate cancer under the trade name Pluvicto .
Novartis also has a number of nuclear drugs under development, most of which use the lutetium-177 isotope .
-
Interpretation of the 2022 Guidelines for Prostate Cancer Screening, Early Diagnosis and Treatment in China (Part 1)
Time of Update: 2022-04-29
*Only for medical professionals to read and reference to interpret the epidemiology, disease types, risk groups and early screening recommendations of prostate cancer in China .
-
"Philippine" long-term vision - case sharing: deep ketone reduction, full monitoring, triptorelin to help prostate cancer testosterone management
Time of Update: 2022-04-29
In order to improve the clinical diagnosis and treatment level of doctors related to urogenital tumors, Yimaitong invited Professor Li Jun from Sichuan Provincial People's Hospital to provide prostate cancer cases, and invited Professor Wang Shaogang from Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology to comment .
